
Pharmaceutical Technology
FIECON Joins Herspiegel To Expand Global Life Science Commercialization Services
By PR Newswire

Strengthening Market Access and Health Economics Capabilities to Support Global Biopharma
YARDLEY, Pa. and LONDON, April 7, 2025 /PRNewswire/ -- Herspiegel, a world leader in pharmaceutical and biotech commercialization services, continues its strategic expansion by joining forces with FIECON, Europe's leading health economics and market access consultancy firm.
This strategic integration expands Herspiegel's proven market access capabilities and enhances Herspiegel's global footprint. The integrated global access services will support patient access to life-saving and life-altering therapies through industry-leading expertise across the access value chain including strategy, health economic modeling, outcomes research, Health Technology Assessments (HTA), value communications, pricing and reimbursement, and Real-World Evidence (RWE).
Herspiegel provides world-class commercialization services, optimizing business outcomes for the world's largest pharmaceutical and biotech organizations. This strategic expansion integrates a team of over 250 employees and further expands the firm's ability to serve clients across the asset lifecycle. The addition of FIECON enhances the firm's European presence with an office in London and deepens its expertise in delivering health economic and market access strategies and evidence to support global reimbursement of medicines and devices. With a success rate of more than 95% in delivering Health Technology Assessments (HTAs) and added capabilities in Europe around Joint Clinical Assessments (JCA), FIECON delivers unmatched value to clients navigating complex market access challenges. "The collaboration with FIECON represents a significant milestone in our expansion strategy," said Brent Herspiegel, CEO of Herspiegel. "Bringing together our commercialization expertise with FIECON's exceptional capabilities in health economics and HTA strengthens our ability to guide clients through complex regulatory and market access challenges. We are committed to delivering integrated, data-driven solutions that enhance commercial success globally."
Kuntal Fisher, CEO of FIECON, commented: "Joining forces with Herspiegel allows us to expand our impact, using economics for the good of humanity with even greater resources and strategic insights. Our shared vision of delivering high-quality, evidence-based solutions makes this partnership a natural fit. We are excited to integrate our expertise in health economics, access strategy, and value communications with Herspiegel's comprehensive commercialization services."
The combined firm will offer an expanded range of services, supporting pharmaceutical and biotech clients globally across the asset lifecycle. With growing demands for robust economic assessments in regulatory approvals and reimbursement processes globally, Herspiegel is poised to set a new standard of commercialization services, enhancing patient experience and access to life-changing therapies.
In this transaction, Piper Sandler & Co. served as exclusive financial advisor and Bird & Bird LLP as legal advisor to FIECON.
Learn more at Herspiegel.com.
Media Contact:
Sue Fee
Marketing Director
Phone: 610-290-3473
1020 Stony Hill Rd, Suite 200, Yardley, PA 19067
https://herspiegel.com/contact-us/
About Herspiegel
Herspiegel is a leading commercialization consulting firm helping life science clients maximize brand potential. With expertise across market access, medical affairs, marketing, and patient services, Herspiegel has supported over 150 pharmaceutical product launches spanning oncology, rare disease, biosimilars, and generalized medicine brands. Our team of MDs, PhDs, MBAs, and pharmacists deliver strategic insights and operational excellence to ensure commercial success.
About FIECON
FIECON is a global life sciences consultancy specializing in economic modelling, outcomes research, health technology assessments, value communications, and pricing and reimbursement strategies. With extensive experience supporting biotech, pharmaceutical, and medical technology companies, FIECON combine commercial strategy and technical rigour to ensure successful therapeutic launches worldwide. FIECON's experienced team partners closely with clients, navigating complex market access environments to deliver impactful solutions that make a meaningful difference to patients globally.
View original content to download multimedia:https://www.prnewswire.com/news-releases/fiecon-joins-herspiegel-to-expand-global-life-science-commercialization-services-302421440.html
SOURCE Herspiegel Consulting
Frequently Asked Questions
What is the significance of Herspiegel's acquisition of FIECON?
This merger significantly expands Herspiegel's global reach and capabilities in health economics and market access, strengthening its ability to support pharmaceutical and biotech clients throughout the product lifecycle.
What services does the combined firm offer?
The combined entity offers a comprehensive suite of services, including market access strategy, health economic modeling, HTA support, value communication, pricing & reimbursement, and Real-World Evidence (RWE).
How does this merger benefit pharmaceutical and biotech companies?
It provides clients with integrated, data-driven solutions to navigate complex regulatory and market access challenges globally, ultimately enhancing commercial success and patient access to therapies.
First published on Mon, Apr 7, 2025
Liked what you read? That’s only the tip of the tech iceberg!
Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!
Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.
Dive into TechDogs' treasure trove today and Know Your World of technology like never before!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending PR Newswire
Cloudzero Launches Optimize To Cut Waste, Boost Cloud ROI
By PR Newswire
Cognizant Recognized As Pega Partner Of The Year For Advancing AI-Powered Enterprise Transformation
By PR Newswire
DXC Relaunches SAP Fast RISE Offering In Mexico, Powered By Microsoft Azure, To Accelerate Secure And Local Digital Transformation
By PR Newswire
Iquanti Announces CEO Transition, Welcomes Arnab Sen As Chief Executive Officer
By PR Newswire
Lummus Completes Acquisition Of NAPCON From Neste, Expanding Digital And AI Capabilities
By PR Newswire
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion